Oura’s Big Bet: From Smart Ring to Health Intelligence Platform
Oura’s $11 billion IPO bet is that a smart ring, paired with subscription software, can evolve into a health intelligence platform built on long-term wearable physiological data rather than one-off gadget sales, reshaping how consumers engage with their own health insights.
Oura did not file for an IPO to be valued as another hardware brand; it filed to be priced as a data and health intelligence company. Last month’s IPO filing came just before CEO Tom Hale appeared on stage at a major beauty and wellness forum, framing the company as “a health intelligence platform that will redefine the future of healthcare.” The implied message to investors is clear: this is not a jewelry business, but a software-and-subscription engine that uses a ring as the on-ramp. With an Oura IPO valuation tied to this story, the company is asking the market to buy into a future where physiological data, not step counts, is the core asset.
Growth Story: Women’s Health, Retail, and the Subscription Moat
If Oura’s IPO narrative has weight, it is because the growth numbers are hard to ignore. Under Hale’s leadership since 2022, annual revenue rose from $220 million to $1 billion, with the company reaching an $11 billion valuation. Oura has sold 5.5 million rings, and roughly half of those sales happened in the last 12 months, a sharp inflection that few smart ring health tech players can claim.
Hale credits three moves: focusing on underserved women’s health use cases, expanding into physical retail to remove friction around sizing, and becoming the first wearable eligible for pre-tax HSA/FSA funds. Yet the more interesting part of the story is not shipments but stickiness. Oura openly describes the ring as hardware onboarding for a behavior-change subscription, with membership priced around £6 a month and retention of 80 percent at year one, rising to 85 percent in years two and three. That subscription moat is the real IPO pitch.
The Physiological Data Thesis: Building a Large-Scale Model
Oura’s central thesis is that the next wave of health tech will be defined by continuous, personalized physiological models rather than static metrics. Hale argues that “everyone’s already got a supercomputer … on their body” and that there should be “a large physiological model that is making predictions about health outcomes in the short term and the long term based on your ground truth of biometrics.”
This is not rhetoric about steps or calories; it is a bid to build what Oura frames as the world’s first large physiological data platform for health insights. The company presents itself as sitting at the intersection of lifestyle optimisation and medical-grade credibility, noting that 11 percent of its ring wearers are medical professionals. In a market full of smart ring health tech and watches, Oura is staking its future on the claim that the value of wearable physiological data compounds over time, turning every night of sleep and every heart-rate trace into training data for its health intelligence platform.
Retention Over Hardware: A Different Wearables Business Model
Most wearables are still sold like phones: a hardware cycle, maybe some services, and a quiet hope you will upgrade in a few years. Oura is trying to invert that logic. The company explicitly defines its category as long-term behavior modification, not jewelry or fashion, and positions the ring as the physical key to a recurring subscription. Hardware becomes the onboarding mechanism, not the profit center.
That choice shows up in the metrics the company highlights. Instead of unit shipments or device refresh cycles, Oura leads with retention and engagement. It claims membership retention of 80 percent after one year and 85 percent in years two and three, benchmarks it says outperform major content platforms at similar stages. The message to investors is blunt: Oura is not betting the Oura IPO valuation on selling you another gadget; it is betting on keeping you in its health intelligence platform for years.
Defensibility, Tariffs, and the Road After the IPO
Oura knows the wearable field is crowded, and it frames defensibility around intellectual property and scientific validation, not price wars. The company points to an IP moat and emphasizes that a meaningful share of its users are medical professionals, using that as evidence it can hold a premium position as other devices flood the category. In this context, the IPO is less an exit than a funding vehicle to deepen its health intelligence platform and expand its physiological model.
Even on practical issues like tariffs, Oura is keen to show resilience. Its chief financial officer has called a 15 percent US tariff on goods from the European Union “totally manageable,” while mentioning that the group has applied some price increases and may consider further measured changes. The company is signaling to public-market investors that it can absorb macro shocks without losing its focus on retention and data. If Oura pulls this off, its IPO will not just price a smart ring; it will test whether markets value a long-term, subscription-first health intelligence platform built on wearable physiological data.
